Markets:

Overview

News

Currencies

International

Treasuries

Atai Beckley N.V - Common Shares (NQ:ATAI)

3.800 +0.140 (+3.83%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Atai Beckley N.V - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference

August 07, 2024

From atai Life Sciences

Via GlobeNewswire

EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves ↗

July 31, 2024

Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.

Via Benzinga

Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD ↗

July 14, 2024

The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...

Via Talk Markets

3 Dirt-Cheap Drug Developers With Blockbuster Potential ↗

July 11, 2024

These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent.

Via InvestorPlace

3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers ↗

July 08, 2024

These psychedelic drug stocks aren't as radical as once thought as institutional awareness and emphasize on their potential increases.

Via InvestorPlace

3 Psychedelic Stocks to Ride to the Moon and Beyond ↗

July 06, 2024

Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market.

Via InvestorPlace

Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns ↗

July 03, 2024

Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks.

Via InvestorPlace

3 Psychedelic Stocks to Buy on the Dip: Summer 2024 ↗

July 02, 2024

These are three of the best psychedelic stocks to buy on the dip for potentially lucrative future growth and returns.

Via InvestorPlace

Clinical-Stage BioTech Drug Stocks Declined 13% In June ↗

July 01, 2024

Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read

Via Talk Markets

atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference

June 26, 2024

From atai Life Sciences

Via GlobeNewswire

Largest Clinical-Stage BioTech Drug Stocks Declined 6% ↗

June 22, 2024

Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they...

Via Talk Markets

atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a

June 20, 2024

From atai Life Sciences

Via GlobeNewswire

Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why ↗

June 09, 2024

Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA.

Via Talk Markets

Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment ↗

June 05, 2024

FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision.

Via Benzinga

What's Going On With MindMed And Psychedelic Stocks? ↗

June 05, 2024

Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD)....

Via Benzinga

atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference

May 31, 2024

From atai Life Sciences

Via GlobeNewswire

atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors

May 23, 2024

From atai Life Sciences

Via GlobeNewswire

ATAI Stock Earnings: ATAI Life Sciences Beats EPS for Q1 2024 ↗

May 15, 2024

ATAI stock results show that ATAI Life Sciences beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates

May 15, 2024

From atai Life Sciences

Via GlobeNewswire

Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week ↗

May 13, 2024

Via Talk Markets

Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon ↗

May 09, 2024

Via Benzinga

Topics Cannabis

Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May ↗

May 05, 2024

We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD.

Via Talk Markets

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

April 24, 2024

From atai Life Sciences

Via GlobeNewswire

Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week ↗

April 23, 2024

A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and...

Via Talk Markets

Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked' ↗

April 19, 2024

Via Benzinga

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗

April 17, 2024

Via Benzinga

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

April 17, 2024

From atai Life Sciences

Via GlobeNewswire

The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD ↗

April 15, 2024

The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases.

Via Talk Markets

Topics Artificial Intelligence

Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD ↗

April 12, 2024

The 5 constituents in the Psychedelic Compound-Based Drug Stocks Index were up 10.0%, on average, last week and are now up 53.9% YTD.

Via Talk Markets

Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

April 03, 2024

Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Atai Beckley N.V - Common Shares (NQ:ATAI)

All News about Atai Beckley N.V - Common Shares

Starting at $3.75/week.

Subscribe Today